BIOMARIN PHARMACEUTICAL INC (BMRN)
US09061G1013 - Common Stock
Notable Friday Option Activity: TWLO, VRT, BMRN
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host...
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.
Investors seeking growth at a reasonable cost should explore BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO®...
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial...
BioMarin Scheduled to Participate in March Investor Conferences
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in...
DOJ reportedly subpoenas BioMarin over sponsored testing programs (NASDAQ:BMRN)
The US Department of Justice has reportedly issued a subpoena to BioMarin Pharmaceutical (BRMN) seeking information related to sponsored testing programs for it
Noteworthy Friday Option Activity: DOMO, BMRN, FND
BioMarin Pharmaceutical Non-GAAP EPS of $0.49 beats by $0.04, revenue of $646.2M beats by $8.63M (NASDAQ:BMRN)
BioMarin Pharmaceutical beats earnings expectations for Q4 2023 with non-GAAP EPS of $0.49. Revenue of $646.2M exceeds estimates by $8.63M.
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted...
Gene Therapy Makers Struggle to Find Patients for Miracle Cures
BioMarin’s hemophilia treatment had only one US patient last year, as drug pioneers discover that scientific achievement doesn’t guarantee financial success.
Paul Singer's Elliott Management adds ETSY, CCI, MTCH; offloads NI, ARM, NE (NYSE:HWM)
Financial writer highlights key moves by Paul Singer's Elliott Management in Q4: new positions in Etsy, BioMarin Pharmaceutical, and Crown Castle, increased...
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host...
3 No-Brainer Stocks to Buy With $200 Right Now
A reasonably small amount of money can go a long way when it's put to work in innovative, industry-leading businesses.
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Enters Oversold Territory (BMRN)
BioMarin Pharmaceutical Larger Than S&P 500 Component Hormel Foods
Noteworthy Thursday Option Activity: BMRN, CLB, PARA
4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains.
Interesting BMRN Put And Call Options For March 15th
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.
Interesting BMRN Put And Call Options For February 2024
BioMarin may be more of an M&A target with activist Elliott pact - analysts
Biomarin (BMRN) stock rose after activist Elliott Management enteraed a cooepratoon pact and a strategic review committee was established
BioMarin may be M&A target with activist Elliott pact - analysts
Biomarin (BMRN) stock rose after activist Elliott Management enteraed a cooepratoon pact and a strategic review committee was established
BioMarin establishes strategic review committee, expands board (NASDAQ:BMRN)
BioMarin (BMRN) said it has established a strategic review committee, temporarily expanded its board and entered into a cooperation agreement with Elliott Investment Management.
BioMarin Announces Governance Enhancements and Value Creation Initiatives
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin CLO Davis sells stock worth $1.3M - filing (NASDAQ:BMRN)
BioMarin Pharmaceuticals EVP and CLO, George Eric Davis, sells over $1.3 million worth of company shares according to an SEC filing.
First Week of BMRN July 2024 Options Trading
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping.
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
Wells Fargo starts BioMarin at overweight, cites activist involvement (BMRN)
Wells Fargo has initiated coverage of BioMarin Pharmaceutical (BMRN) with an overweight rating, stating that the new CEO and activist investor involvement could